Jafron Biomedical (China) Top Management

Jafron Biomedical Management Team Effectiveness

The company has return on total asset (ROA) of 0.1052 % which means that it generated a profit of $0.1052 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.2476 %, meaning that it generated $0.2476 on every $100 dollars invested by stockholders. Jafron Biomedical's management efficiency ratios could be used to measure how well Jafron Biomedical manages its routine affairs as well as how well it operates its assets and liabilities. At present, Jafron Biomedical's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Other Assets is expected to grow to about 272.2 M, whereas Intangible Assets are forecasted to decline to about 53.5 M. The current year's Common Stock Shares Outstanding is expected to grow to about 880 M. The current year's Net Income Applicable To Common Shares is expected to grow to about 1.4 B

Jafron Biomedical Workforce Comparison

The company has Profit Margin (PM) of 0.31 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.42 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.42.

Jafron Biomedical Benchmark Summation

Jafron Biomedical Notable Stakeholders

The success or failure of an entity such as Jafron Biomedical often depends on how effective the management is. Jafron Biomedical management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Jafron management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Jafron management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.

Please note, the presentation of Jafron Biomedical's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Jafron Biomedical's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Jafron Biomedical's management manipulating its earnings.

When running Jafron Biomedical's price analysis, check to measure Jafron Biomedical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Jafron Biomedical is operating at the current time. Most of Jafron Biomedical's value examination focuses on studying past and present price action to predict the probability of Jafron Biomedical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Jafron Biomedical's price. Additionally, you may evaluate how the addition of Jafron Biomedical to your portfolios can decrease your overall portfolio volatility.